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Whole-genome sequencing of bladder cancers
reveals somatic CDKN1A mutations and
clinicopathological associations with mutation
burden
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Bladder cancers are a leading cause of death from malignancy. Molecular markers might
predict disease progression and behaviour more accurately than the available prognostic
factors. Here we use whole-genome sequencing to identify somatic mutations and
chromosomal changes in 14 bladder cancers of different grades and stages. As well as
detecting the known bladder cancer driver mutations, we report the identiﬁcation of recurrent
protein-inactivating mutations in CDKN1A and FAT1. The former are not mutually exclusive
with TP53 mutations orMDM2 ampliﬁcation, showing that CDKN1A dysfunction is not simply
an alternative mechanism for p53 pathway inactivation. We ﬁnd strong positive associations
between higher tumour stage/grade and greater clonal diversity, the number of somatic
mutations and the burden of copy number changes. In principle, the identiﬁcation of
sub-clones with greater diversity and/or mutation burden within early-stage or low-grade
tumours could identify lesions with a high risk of invasive progression.
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B
ladder cancer is the seventh most common cancer in the
developed world, with tobacco smoking a major cause
(http://www.wcrf.org/cancer_statistics/developed_coun-
tries_cancer_statistics.php). Management of non-muscle-invasive
and/or low-risk disease (pTa, papillary, or ﬂat carcinoma in situ)
focuses on prevention of progression and identiﬁcation of
patients likely to develop high-risk tumours (pT1G3, high grade,
invading lamina propria) in order to offer them early, aggressive
intervention, including radical cystectomy1. However, there is a
likelihood of overtreating some pTa or pT1 tumours that would
never have progressed to the more life-threatening muscle-
invasive disease (pT2þ , invading muscularis propria). Two
different genetic T1G3 sub-types have been reported, one derived
from pTa disease with FGFR3 and HRAS overexpression and/or
mutations, and the other from ﬂat carcinoma in situ with TP53,
RB1 and PTEN mutations and/or loss2. Whole-exome sequencing
of bladder tumours has recently identiﬁed mutations of
chromatin-remodelling genes, such as KDM6A and MLL3
(ref. 3), and of STAG2, which encodes a protein involved in
sister chromatid cohesion4–6. Moreover, four mutation signatures,
principally comprising different combinations of C:G4T:A and
G:C4C:G substitutions, have been detected in some bladder
cancers, although their origins remain unclear7. Whole-genome
sequence data at sufﬁciently high depth for comprehensive variant
calling have not previously been reported for bladder cancers.
Here we perform whole-genome sequencing of bladder cancers
of various stages and grades to search for driver mutations,
chromosome-scale somatic changes, mutation signatures and
clonal structures. We report the identiﬁcation of mutations in the
p53 effector CDKN1A (p21WAF1/CIP1) and the protocadherin
FAT1, describe the genomic landscape of the set of cancers, and
detect associations between tumour stage and measures of
mutation burden.
Results
Overview of the bladder cancer genome. Our discovery set for
whole-genome sequencing comprised 14 bladder cancers
(Table 1), which were sequenced at a median depth of B80 ,
alongside paired constitutional DNA from peripheral blood.
Making use of the Stampy and Platypus programs for mapping,
aligning and calling variants, the number of somatic base sub-
stitution mutations (single nucleotide variants (SNVs)) called
with high conﬁdence ranged from 27,490 to 121,016 per cancer
(median¼ 88,215). Of these, a median of 219 changes (range 82–
585) were potentially functional (non-synonymous, splice site,
stop-gain or stop-loss) substitutions within protein-coding
regions. The mean non-synonymous:synonymous mutation ratio
was 1.76. Other mutation summary statistics are shown in Table 2
and Supplementary Table 1.
The genome-wide SNV spectrum (Fig. 1) showed no single
predominant mutation type, with C:G4T:A changes being most
common, followed by T:A4C:G and C:G4G:C. This mutation
spectrum was broadly similar across all 14 tumours (Fig. 1;
Supplementary Fig. 1) and was signiﬁcantly different from all the
four recently described bladder cancer mutation signatures (1b, 2,
5 and 13)7. However, our mutation spectrum was similar to
signature 1b, related to spontaneous demethylation of methyl
cytosine, across most substitutions apart from G:C4A:T and
C:G4G:C. The signature proﬁles of the somatic mutations in our
samples differed subtly at the exomic and genome-wide levels
(Fig. 1). C:G4T:A changes, for example, were more common in
the exome than whole genome (41 versus 33%, respectively),
perhaps reﬂecting the greater G:C content in the former.
The number of high-conﬁdence somatic insertion–deletion
(indel) mutations of a few base pairs (bp) ranged from 5,118 to
26,407 per tumour (median¼ 21,704). There was a strong
correlation between the numbers of SNVs and indels in each
Table 1 | Demographic and clinicopathological features of the patients and their bladder cancers.
Tumour
no.
Age,
years
Gender Smoker? Occupation Stage Grade Type Background
urothelium
Cystectomy? Follow-up to
September 2013
4062 69 F Ex- Not known pTa G2 Papillary Normal No No recurrence
4070 74 M Passive Steel works pTa G2 Papillary Normal No Recurrence, G1pTa
4078 56 M Current Epoxy resin
worker
pTa G2 Papillary Normal No Did not attend
follow-up
4101 81 M Ex- Sheep
farmer
pTa G1 Papillary Normal No No recurrence
4121 71 F Never Supervisor pTa G2 Papillary Normal No Died due to
metastatic bladder
cancer
635 85 M Ex- Plumber pT1 G3 Papillary/solid Cis No Died
709 73 F Current Farm
worker
pT1 G3 Papillary/solid Not sampled No Alive
745 83 F Ex- Cleaner pT1
N0
G3 Papillary/solid Cis Yes Alive
799 87 M Ex- Coal mining pT1 G3 Papillary/solid Normal No Died
3010 78 F Ex- Dry cleaner pT1 G3 Papillary with squamous
differentiation
Not sampled No Died
451 78 M Ex- Engineer pT2 G3 Papillary/solid Not sampled No Died
615 75 F Ex- Secretary pT2 G2 Papillary Normal No Died
2010 76 F Ex- Warehouse
packer
pT3
N2
G3 Solid with squamous
differentiation
Low-grade
dysplasia
Yes Died
3008 82 F Ex- Steel works pT3b G3 Papillary/solid with
squamous differentiation
Cis Yes Died
3034 77 F Never Ofﬁce
worker
pT3a
N0
G3 Solid Cis Yes Alive
cis, carcinoma in situ; F, female; M, male.
Stage and grade are shown according to TNM 7th edition. Samples were removed at transurethral resection, except where cystectomy is indicated. Detailed follow-up data are shown for those presenting
with pTa disease, whereas binary survival data are shown for those with invasive disease.
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cancer (details not shown). A median of 31 indels (range 6–54)
per tumour were potentially functional within coding regions
(frameshift, stop-gain, stop-loss or splice site).
We searched for regional SNV and indel hotspots (including
‘kataegis’) genome-wide within 1Mb windows (Supplementary
Fig. 2). Most of the hotspot regions identiﬁed lay near
centromeres and telomeres, probably reﬂecting the increased
difﬁculty in mapping and calling variants there, but possibly
resulting from impaired access of DNA repair machinery to these
heterochromatic sites. We also identiﬁed several euchromatic
mutation hotspots, but these could all be accounted for by
(i) large duplicated regions prone to variant miscalling (generally
present in many tumours) or (ii) local copy number increases
(generally present in single cancers).
We validated a subset of mutations using an Ion Torrent 150
cancer-gene panel (see Methods). Ninety-seven per cent of
variants reported using the Illumina-Stampy–Playtpus pipeline
were conﬁrmed by the Ion Torrent technology.
Structural variation. All 14 cancers with genome-wide sequence
data were analysed for copy number changes using OncoSNP-
Seq. In addition, a sub-set of 10 cancers was analysed using
Illumina Omni1M SNP arrays, with high concordance between
the methods (median 75.6%). Somatic copy number changes were
present in all 14 genomes (Supplementary Fig. 3; Supplementary
Data 1). The proportion of the genome showing copy number
changes ranged from 12% (#4101) to 69% (#3034). Frequent
large-scale copy number changes (found in six or more tumours)
included gains of 1q, 3q and 8q, as well as loss of chromosome 9.
Very few regions of high-level copy number gain were found, an
exception being ampliﬁcation around the CCND1 oncogene on
chr11q13.3 and at the FGFR3 locus on chr4p16.3, each in a single
cancer (#4121 and #615, respectively). Two cancers (#615 and
#3008) had acquired homozygous deletions at the CDKN2A locus
(chr9p21.3), and other homozygous deletions present in single
cancers involved genes such as PPARGC1A, RFX3 and FAT1
(Supplementary Table 2). With the exception of CDKN2A and
FAT1 (see below), we found no good evidence from our own or
The Cancer Genome Atlas (TCGA) mutation data to support the
notion that any of the homozygously deleted genes acted as
bladder cancer tumour suppressors.
We speciﬁcally searched for chromosome arms that had
undergone chromothripsis, which we deﬁned for convenience as
evidence of at least 10 copy number and/or loss of heterozyosity
(LOH) transitions on a single arm. Cancer #745, which had the
most chromosomally unstable genome of the tumours analysed,
showed chromothripsis involving chromosome arms 3p, 5q, 6p
Table 2 | Summary genome proﬁles of the cancers.
Tumour no. Type Tumour % ESM GSM CNV % No. of CNVs Clonality
4062 pTa 70 146 34,966 14 654 2
4070 pTa 90 137 33,861 14 658 1
4078 pTa 80 179 — — — 2
4101 pTa 80 154 32,608 12 669 1
4121 pTa 70 235 40,678 19 729 2
635 pT1 70 920 113,970 42 633 2
709 pT1 70 541 110,745 39 741 2
745 pT1 80 427 122,353 67 888 20
799 pT1 80 272 123,701 47 629 13
3010 pT1 90 350 139,673 33 812 16
451 pT2 90 385 111,643 20 644 5
615 pT2 90 892 108,578 31 703 3
2010 pT2 70 482 122,547 53 710 29
3008 pT2 80 402 117,965 24 557 36
3034 pT2 80 495 99,990 69 1,233 4
clonality, number of sub-clonal clusters estimated by Pyclone; CNV %, per cent of genome affected by copy number changes; ESM, number of exomic somatic mutations; GSM, number of genomic
somatic mutations; no. of somatic CNVs, number of discrete CNVs; tumour %, percentage of tumour cells in the sample.
Note that only exome sequence data were available for #4078.
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Figure 1 | Somatic SNV spectrum genome-wide. The proportions of somatic SNVs of each type are shown for each of our cancers (whole genome or
exome) in comparison with the TCGA bladder cancer data (exomes).
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and X (Supplementary Fig. 4). Three other cancers had one or
two arms with chromothripsis, but no recurrent region was
observed across the set of 14 tumours.
Using BreakDancer followed by speciﬁc quality ﬁltering (see
Methods), we found between 618 and 3,550 predicted inter-
chromosomal breakpoints in each tumour. To reduce complexity,
we focussed on anchor points lying within gene boundaries,
resulting in a range of 18–86 inter-chromosomal changes per
cancer (Supplementary Data 2), although no anchor points lay
within an exon.
Driver genes. For discovery of new bladder cancer-driver muta-
tions, we restricted our analysis to protein-coding regions. In
addition to our discovery set cancers, exome sequence data from
one additional stage pTa bladder cancer were available, making a
total of 15 bladder cancers analysed for driver gene detection. We
ﬁltered somatic mutations to exclude all base substitutions with
moderate or benign predicted functional effects (Sorting Intolerant
From Tolerant (SIFT) score40.2 and Polyphen2 scoreo0.8). All
protein-truncating and splice-site mutations were retained. We
then removed from this list genes that were mutated in only one
cancer. We inspected all mutant sequencing reads manually and
excluded any of evidently poor local quality. Nineteen genes sur-
vived this process (Table 3; Fig. 2), including several—for example,
TP53, FGFR3, ARID1A and KDM6A—which at the time of analysis
had previously been identiﬁed as bladder cancer-related genes4,5,8,9.
Prioritized genes that had not previously been reported as
bladder cancer drivers included STAG2, B3GNT9, FAT1 and
Table 3 | Known bladder cancer-driver mutations and other mutations in genes fulﬁlling the ﬁltering criteria for further analysis.
Tumour no. Chr Position (B37) Gene Details LOH
709 1 27,099,037 ARID1A NM_006015:c.3453_3454insA:p.S1151fs 0
3008 1 27,106,378 ARID1A NM_006015:c.A5989G:p.N1997D 1
635 1 237,765,394 RYR2 NM_001035:c.G4666C:p.E1556Q 0
3034 1 237,791,238 RYR2 NM_001035:c.C6298T:p.R2100W 0
2010 1 237,947,202 RYR2 NM_001035:c.G12190A:p.E4064K 0
4070 4 1,803,568 FGFR3 NM_000142:c.C746G:p.S249C 0
4121 4 1,803,568 FGFR3 NM_000142:c.C746G:p.S249C 0
615 4 1,803,568 FGFR3 NM_000142:c.C746G:p.S249C 0
4078 4 1,806,099 FGFR3 NM_000142:c.A1118G:p.Y373C 1
3010 4 1,806,099 FGFR3 NM_000142:c.A1118G:p.Y373C 1
4101 4 1,806,153 FGFR3 NM_000142:c.C1172A:p.A391E 0
4078 4 187,522,477 FAT1 NM_005245:c.T11586A:p.Y3862X 1
451 4 187,542,642 FAT1 NM_005245:c.G5098T:p.E1700X 0
3034 6 36,652,054 CDKN1A NM_000389:c.176_177insG:p.L59fs 0
745 6 36,652,071 CDKN1A NM_000389:c.T193A:p.W65R 1
2010 9 21,974,695 CDKN2A NM_000077:c.132_133insA:p.Y44_G45delinsX 1
4062 9 135,776,983 TSC1 NM_001162427:c.C2342T:p.S781F 1
4062 9 135,781,212 TSC1 NM_001162427:c.C1600G:p.P534A 1
4062 9 135,781,386 TSC1 NM_001162427:c.C1426G:p.Q476E 1
3008 9 135,781,446 TSC1 NM_001162427:c.1365delC:p.P455fs 1
4062 12 49,427,530 MLL2 NM_003482:c.G10958C:p.G3653A 0
4062 12 49,427,912 MLL2 NM_003482:c.G10678A:p.D3560N 0
4121 12 49,431,499 MLL2 NM_003482:c.G9640C:p.E3214Q 0
4121 12 49,431,871 MLL2 NM_003482:c.G9268C:p.E3090Q 0
4121 12 49,431,937 MLL2 NM_003482:c.G9202A:p.E3068K 0
4101 12 49,434,561 MLL2 NM_003482:c.6991delC:p.L2331X 0
4101 12 49,438,067 MLL2 NM_003482:c.C5104T:p.R1702X 0
451 12 49,439,934 MLL2 NM_003482:c.4607_4608insA:p.S1536fs 0
451 12 49,445,797 MLL2 NM_003482:c.1668delG:p.P556fs 0
3008 15 33,261,489 FMN1 NM_001103184:c.G1744A:p.V582I 0
3034 15 33,359,823 FMN1 NM_001103184:c.C263T:p.S88L 1
615 16 67,183,392 B3GNT9 NM_033309:c.C997T:p.H333Y 0
615 16 67,183,539 B3GNT9 NM_033309:c.C850G:p.P284A 0
745 16 67,184,036 B3GNT9 NM_033309:c.T353A:p.L118Q 1
3010 17 7,577,094 TP53 NM_001126115:c.C448T:p.R150W 1
2010 17 7,577,127 TP53 NM_001126115:c.G415A:p.E139K 1
799 17 7,578,395 TP53 NM_001126115:c.C139T:p.H47Y 0
799 17 7,578,475 TP53 NM_001126115:c.C59T:p.P20L 0
615 18 10,784,798 PIEZO2 NM_022068:c.G2476C:p.D826H 0
4070 18 11,066,210 PIEZO2 NM_022068:c.C76T:p.R26X —
615 X 44,820,628 KDM6A NM_021140:c.326_329del:p.109_110del —
4070 X 44,922,729 KDM6A NM_021140:c.1591_1606del:p.531_536del —
3034 X 44,941,984 KDM6A NM_021140:c.3234_3235insT:p.P1078fs —
4078 X 44,942,842 KDM6A NM_021140:c.3422_3423insC:p.S1141fs —
799 X 44,949,105 KDM6A NM_021140:c.3666_3667insG:p.A1222fs —
4101 X 123,196,821 STAG2 NM_006603:c.1709delC:p.A570fs —
451 X 123,200,065 STAG2 NM_006603:c.2137_2138insA:p.Y713_K714delinsX —
3010 X 123,202,462 STAG2 NM_006603:c.T2314C:p.C772R —
Chr, chromosome; LOH, loss of heterozyosity.
The details of the mutations are shown as: reference transcript: DNA change: protein change. For LOH: 1, present; 0, absent.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4756
4 NATURE COMMUNICATIONS | 5:3756 | DOI: 10.1038/ncomms4756 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
CDKN1A. We chose STAG2, MLL2/KMT2D and CDKN1A for
further replication testing, based on the presence of at least one
protein-truncating mutation and the paucity of mutations
previously reported in cancers. Furthermore, all three genes were
excellent functional candidates. STAG2 protein is required for the
cohesion of sister chromatids after DNA replication and interacts
directly with RAD21 in the cohesin complex. MLL2 is a histone
methyltransferase. CDKN1A (p21WAF1/CIP1) is a regulator of
progression in G1 and S phases of the cell cycle10, and is
controlled by p53 in response to a variety of stress stimuli. p21
expression changes have been found in multiple tumour types,
but mutations have very rarely been reported. We validated the
STAG2 and CDKN1A changes detected by whole-genome
sequencing using Sanger sequencing in the discovery set of
tumours, and then undertook replication testing in a set of 35
additional bladder cancers (Supplementary Table 3). Four further
protein-truncating and missense CDKN1A mutations were found
(Supplementary Table 4), and of the total of six CDKN1A-mutant
cancers in our set, two (33%) showed LOH. One of the 35
replication cancers had a somatic mutation in STAG2. This was a
splice-site change that we showed to affect mRNA splicing
(Supplementary Fig. 5). Subsequent to us performing this work,
STAG2- and MLL2/KMT2D-driver mutations were reported in
bladder cancers by other groups4–6, and we did not proceed to
replication test MLL2/KMT2D in our own samples.
Two of our 15 sequenced cancers had acquired nonsense
mutations in FAT1 (Table 3), which encodes a large proto-
cadherin that contains multiple transmembrane repeats. One of
these two cancers showed LOH at FAT1. In addition, we detected
a third cancer with predicted homozygous deletion of FAT1
(Supplementary Table 2). Although testing of FAT1 was
impractical in our replication samples owing to moderate DNA
quantity and the large size of the FAT1 gene, we performed in
silico replication using publicly available data from 99 bladder
cancers in the TCGA consortium. That group’s data showed two
tumours with protein-truncating FAT1 mutations and a further
cancer with a missense change, p.Ile2276Met, predicted to have
severe functional effects (SIFT¼ 0.05, Polyphen2¼ 0.87).
We then examined all the bladder cancer-driver genes for
mutations outside protein-coding regions. Two SNV mutations in
untranslated regions were found, one in the 30UTR of ARID1A
and the other in the 30UTR of FGFR3, but neither had predicted
effects on miRNA binding or mRNA structure (details not
shown). No promoter mutations were detected. We then
examined 50 kb regions around the driver genes for somatic
mutations that might disrupt regulatory elements. On the basis of
the reasoning that the most functionally profound changes were
likely to involve severe disruption of regulatory regions or motifs,
we focused on indels of Z5 bp. A single change fulﬁlling these
criteria was found, a 13-bp deletion upstream of FGFR3
(chr4:1,754,064; 50-TCCCCCGCCCCAAC-304T) that removed
a site shown to be methylated in multiple tissue types (http://
genome.ucsc.edu/).
Pathway analysis (Supplementary Fig. 6) reassuringly found
‘bladder cancer’ to be ﬁrst in the list of mutated gene sets. Less
expected were the ﬁndings that mutations in Wnt signalling,
adherens junction and Notch signalling pathways were over-
represented, given that none of the top driver mutations played
principal roles in any of these processes.
The MDM2 amplicon. Our copy number assessment had iden-
tiﬁed a small, recurrent duplication/ampliﬁcation on chromo-
some 12 (minimal region 69.1–70.0Mb) that involved the MDM2
gene, a known driver oncogene in bladder cancer11 and presumed
target of the copy number gain (Figs 2 and 3). None of our
cancers, whether with or without copy number gain at this site,
and no TCGA cancers harboured additional activating mutations
in MDM2. In addition to MDM2, genes contained within the
amplicons included NUP107, CPM, CPSF6, LYZ, YEATS4 and
FRS2. The chr12 duplication was present only in invasive lesions
and, as expected, was mutually exclusive with TP53 mutations.
The availability of whole-genome sequence allowed us to
investigate the amplicon structure in detail, using copy number
predictions and allele frequency data for both germline
polymorphisms and somatic mutations (Fig. 3). The amplicons
in all four cancers had a proximal boundary close to
chr12:69.1Mb, although only two cancers appeared to share an
identical breakpoint at this site. The distal amplicon boundary
was more variable, ranging from chr12:70.2 to chr12:71.9Mb
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(Fig. 3). We noted that two regions of homology, to chromosomes
5q and 8q, lay close to the breakpoint sites, but we found no
evidence of translocations between the MDM2 region and these
sites. It appeared that all the amplicons resulted from local
structural rearrangements.
In none of the four cancers was the region of ampliﬁcation
structurally simple. Estimated copy number at MDM2 varied
from 3 to 8. However, total copy number and allelic ratios varied
along each amplicon, with intercalated regions of high- and low-
level ampliﬁcation. MDM2 was located in a region of high-level
copy number (CN¼ 8) in three of the four tumours (#615, #635
and #709), and within a region of single copy gain in the
remaining tumour (#745). Allele-speciﬁc assessment within the
amplicons (Fig. 3) showed severe allelic asymmetry in the three
cancers with high-level gain, suggesting that a single copy of
chromosome 12 had become destabilized in the region. Somatic
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Figure 3 | TheMDM2 amplicon. SNV allele frequencies (left-hand y axis) across each of the amplicons in the four cancers (#615, #635, #709 and #745)
with copy number gain around MDM2 are shown. The red dots correspond to variants present in the constitutional DNA, green to the same variants in the
tumours and blue to somatic SNVs. Estimated copy number in each region (right-hand y axis) is shown as a black line for guidance, although close
inspection of the allelic frequency changes suggests that the level of amplicon complexity is not fully captured. A tumour without MDM2 region
ampliﬁcation (#4101) is shown for comparison. The position of MDM2 (chr12:69,201,971–69,239,320) is shown below the plots.
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SNV and, particularly, indel frequencies were grossly elevated
above background and had independently been identiﬁed as
regions of possible kataegis (Supplementary Fig. 2). The elevation
in indel mutation numbers could not solely be accounted for by
the increased total copy number, suggesting that it might be
linked to the region’s instability in some way, although errors in
mapping of chimaeric reads could not be excluded. The SNV
mutation spectrum within the amplicon did not differ signiﬁ-
cantly from the genome-wide spectrum of each cancer (Fig. 1).
Overall, these data strongly suggested that a single copy of
chromosome 12 had acquired a fundamentally destabilized region
around MDM2 in at least three, and possibly four, tumours.
TP53 and CDKN1A protein expression in bladder cancers.
Immunohistochemistry (IHC) was performed on 46 additional
bladder cancer patients for both p53 and p21 proteins.
Using cutoff points of 5, 10 or 20% of tumour cells displaying
nuclear immunoreactivities for both proteins, we observed no
signiﬁcant correlation between TP53 and CDKN1A expression
(Supplementary Table 5; Supplementary Fig. 7). The results
remained similar with full semi-quantitative scores.
Evolution and clonal structure. Clonal structure was evaluated
using Pyclone, incorporating the bladder cancer-driver mutations
and 50 random SNVs (Fig. 4; Supplementary Data 3). Two pTa
tumours (#4070 and #4101) showed only a single clonal cluster
and three cancers (#4078, #709 and #4121) appeared monoclonal
apart from one outlier. The other cancers showed good evidence
of multiple clones, with a maximum number of 36 clonal clusters
in tumour 3008. Tumour 451 was notable for its predicted early
divergence into two clones, each distinct from the other but with
high levels of similarity within each sub-clone. We tested the
hypothesis that cancers with greater genetic diversity (larger
numbers of sub-clones) would also have higher SNV/indel bur-
den and/or a greater proportion of the genome showing copy
number aberrations, and found that both were the case (Spear-
man’s r¼ 0.83, P¼ 0.0002 and r¼ 0.61, P¼ 0.021, respectively).
Clinicopathological-molecular associations. The number of
cancers analysed by whole-genome sequencing was too low to
reliably analyse associations between clinicopathological variables
and speciﬁc mutations, although we noted that FGFR3 mutations
were more common in pTa tumours, as expected. All invasive
pTa
pT1
pT2
635 709 745 799 3010
451 615 2010 3008 3034
4062 4070 4078 4101 4121
Figure 4 | Clonality across the tumours. Summary of the frequency distributions of the key somatic mutations plus 50 random SNVs (y axis) for each
tumour. The x axis shows the frequency of each mutant between 0 and 1. See Supplementary Data 3 for more details.
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(pT1 and pT2) lesions had TP53, CDKN1A or CDKN2A muta-
tions or MDM2 ampliﬁcation, and none of these genes had
changes in pTa tumours. We also tested for differences in
mutation burden among the non-invasive, early invasive and
muscle-invasive tumour groups. Since no measure of clonal
structure or mutation burden differed signiﬁcantly between pT1
and pT2 cancers (P40.15, N¼ 10, Wilcoxon test), we combined
these groups for further analysis. We found that the number of
somatic mutations, the proportion of the genome affected by copy
number changes (a surrogate for chromosomal instability) and
the number of predicted sub-clones were all signiﬁcantly posi-
tively associated with increasing stage (P¼ 0.0047, P¼ 0.0046 and
P¼ 0.060, respectively; Wilcoxon test, pTa versus pT1/pT2).
Grade (G1,2 versus G3), which was positively correlated with
stage, was similarly associated with the same three molecular
burden variables (P¼ 0.0041, P¼ 0.0062 and P¼ 0.0082). Age,
sex and smoking status (ever versus never) were not associated
with any of the three measures of mutation burden and diversity.
Mutation spectra (proportions of different types of SNVs) were
not in general associated with clinicopathological variables,
including age and smoking history. One possible exception was
the proportion of T:A4G4C changes, which was positively
associated with higher stage (P¼ 0.037, Kruskal–Wallis test).
Discussion
Our whole-genome sequencing of bladder carcinomas of various
sub-types has conﬁrmed the known bladder cancer-driver genes,
including our independent discovery of STAG2-driver mutations
that have recently been reported by other groups4–6 (Table 3;
Fig. 2). We additionally identiﬁed and replicated mutations in
CDKN1A that are strongly predicted to impair protein function,
in both our discovery and replication data sets. In some cases,
these CDKN1A changes were accompanied by loss of
heterozygosity. Our ﬁndings were further supported by
inspection of TCGA exome sequencing data from 99 bladder
cancers, which at the time of analysis in October 2013 showed
two somatic SNVs in CDKN1A, one predicted to have strongly
deleterious effects (p.Gly61Val, SIFT 0.00, Polyphen2 0.997) and
the other to have possibly damaging effects (p.Asp136His,
SIFT¼ 0.11, Polphen2¼ 0.553). Some years ago, Lacombe
et al.12 reported a single bladder cancer, out of 27 analysed,
with a protein-truncating CDKN1A mutation, and we
additionally note that contemporaneous TCGA bladder cancer
exome sequencing data (January 2014) show 18 CDKN1A-mutant
bladder cancers of a total of 130 analysed13. We conclude that
CDKN1A is a tumour suppressor gene in bladder carcinoma, and
we note that its inactivation is a bladder-speciﬁc change, since
41% of cancers of other sites harbour CDKN1A mutations
(http://cancer.sanger.ac.uk/cosmic/gene/overview?ln=Cdkn1a).
CDKN1A and CDKN2A mutations were mutually exclusive in
both our and TCGA data. Although p21, the protein encoded
by CDKN1A, acts downstream of p53, we found one cancer
(#1992) from our full set of 50 tumours to have both CDKN1A
(p.Tyr77del) and TP53 (p.Arg213Pro) mutations (details
not shown) and another (#745) to have CDKN1A mutation
(p.Trp65Arg) and low-levelMDM2 ampliﬁcation (Supplementary
Table 4). Interestingly, p21 protein has variably been described as
having oncogenic and anti-oncogenic effects in a number of
cancer types14. The genetic data strongly suggest that loss of p21
function promotes the growth of bladder carcinomas. Our genetic
data also strongly suggest that loss of p21 function may augment
defects caused by inactivation of p53, but does not act as a simple
substitute. Our IHC data support this contention. Cancers
with low or absent p53 might have various underlying causes
(including not only protein-destabilizing TP53 mutations, MDM2
ampliﬁcation, chr9p21 deletions involving p14ARF, but also a
normal p53 pathway. However, stabilization of p53 protein is
generally accompanied by pathogenic missense TP53 mutations,
and these cancers would not generally be expected to activate p21
expression15. The ﬁnding by ourselves and others16 that a
proportion of bladder cancers expresses both p53 and p21
suggests that p21 can be activated by a p53-independent pathway
in these tumours, providing a rationale for some of them
acquiring both p21 and p53 mutation.
In addition to identifying CDKN1A mutations, we have
highlighted inactivating FAT1 mutations as possible bladder
cancer drivers, on the basis of protein-truncating mutations and
deletions in our own and TCGA data. FAT1 is a tumour
suppressor in Drosophila and an excellent candidate for having a
similar role in humans. It functions in cell adhesion and is
expressed in the urinary tract. However, FAT1 is an extremely
large gene, and hence it is not yet possible to assign driver or
passenger status to the mutations we have found. We additionally
identiﬁed recurrent mutations in RYR2, FMN1, B3GNT9 and
PIEZO2 in our discovery set of cancers, but the importance of
these genes for bladder carcinogenesis remains uncertain.
The mutation spectra of our bladder cancers did not closely
match any of the 22 speciﬁc signatures previously reported,
although there were similarities to signature 1b (ref. 7).
Speciﬁcally, we did not ﬁnd evidence of a carcinogen signature
or a preponderance of G:C4C:G mutations reported in some
bladder cancers17. The differences between the two data sets
might in part result from the smaller size of our cohort, or from
differences in the types of tumour sequenced, but we suggest that
the G:C4C:G mutation signature is not common in bladder
cancer.
The use of genome-wide deep sequencing allowed us to
perform extensive work on structural variations, including copy
number changes and translocations. Although no recurrent
translocations with intragenic breakpoints were found, several
focal regions of deletion and gain were detected. Speciﬁcally, we
characterized the structure of the recurrent ampliﬁcation around
MDM2, which was found in 4 of 10 invasive tumours. This
analysis showed that in most of these tumours, there was
heterogeneity in copy number across the amplicon. Although
there was no evidence of activating MDM2 mutations, ampliﬁca-
tion in most cancers was greatly asymmetric with respect to
constitutional polymorphisms, suggesting that one copy of
chromosome 12 became locally destabilized, leading to the
observed rearrangements and, perhaps, an elevated frequency of
small indels. Breakdancer analysis did not indicate the transloca-
tion of the MDM2 amplicon to any other chromosome, although
we cannot exclude its location on double-minute chromosomes.
There were clear associations between tumour stage and
molecular features. In general, invasive tumours had larger
burdens of mutations of all types, including SNVs and copy
number changes. The invasive tumours also showed greater
clonal diversity. With the possible exception of T:A4G4C
changes, there was no clear association between stage and SNV
mutation spectrum, suggesting that invasion was not driven by
mutagen exposure or speciﬁc defects in DNA repair (although
defects causing chromosomal instability remained a possible
cause of invasive behaviour). It will be of interest for larger future
studies to assess associations between molecular phenotypes, such
as mutation burden, and other measures of bladder cancer
behaviour, including prognosis. Furthermore, it will be important
to test the scenario that some early-stage bladder cancers harbour
sub-clones with p53 or p21 inactivation, and/or greater diversity
and/or mutation burden, thus allowing the identiﬁcation of
tumours with a high risk of progression to invasive disease and
permitting more appropriate and intensive management.
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Methods
Sample description. Ethics approval was obtained from South Yorkshire Research
Ethics Committee (project 10/H1310/73), Oxfordshire Research Ethics Committee
C (project 09/H0606/5), Leeds (East) Research Ethics Committee (project 04/
Q1206/62) and NRES Committee London-Bromley (project 13/LO/0540).
The discovery set of tumour cancers with whole-genome sequence data
comprised 14 bladder cancers, paired with peripheral blood, that had been
collected from unrelated individuals presenting to the Urology Department, Royal
Hallamshire Hospital, Shefﬁeld, between June 2008 and September 2011. Four
cancers were of low-grade papillary morphology (pTaG1-2: #4062, #4070, #4101
and #4121), ﬁve were high grade invading the lamina propria (pT1G3: #635, #709,
#745, #799 and #3010, with #635 and #3010 subsequently becoming muscle
invasive) and ﬁve were muscle invasive (pT2-pT3: #451, #615, #2010, #3008 and
#3034). Exome sequence data were available from a further low-grade cancer,
#4078. All tumours were sampled at transurethral resection or cystectomy and had
not previously received any other therapy. The presence of at least 70% cancer cells
in the tumour specimens was conﬁrmed by routine histological assessment.
Genomic DNA was extracted from each tumour and paired blood sample using
standard methods.
The replication set comprised 35 frozen biopsies of bladder carcinomas (16 pTa
or pTis, 10 pT1G3, 9 pT2) from patients who had donated samples to the Oxford
Radcliffe Biobank. Each sample was microdissected to maximize the amount of
tumour, using haematoxylin and eosin-stained slides as a guide. After conﬁrming
that each specimen included a majority of cancer cells, DNA was extracted using
standard methods of digestion with Laird’s lysis buffer plus proteinase K, followed
by phenol–chloroform extraction and ethanol precipitation. For selected cancers
where mutations were detected, the somatic origin of those changes was conﬁrmed
by microscope-guided dissection of normal tissue from the tumour specimen.
The IHC set comprised samples from 46 patients with muscle-invasive bladder
cancer, treated with radical radiotherapy at Leeds Teaching Hospitals NHS Trust
from January 2006 to February 2009 as described in and one further patient. The
median patient age was 76.5 years (range 57.8–86.5); 33 were male (72%) and
13 female (28%). Suitable invasive tumour areas were identiﬁed by a consultant
histopathologist (SB) on haematoxylin and eosin sections from formalin-ﬁxed
parafﬁn-embedded bladder chips obtained at pre-radiotherapy transurethral
resection. Up to ﬁve 0.6mm tissue microarray (TMA) cores per patient were
embedded into a single recipient block, from which 0.4 mM sections were taken for
IHC staining.
Whole-genome sequencing. Sequencing in the discovery set was performed as
part of the WGS500 project using a dedicated pipeline. Samples were quantiﬁed
using the Qubit system (Invitrogen) and sequencing libraries constructed from 1 mg
DNA using the NEBNext DNA Sample Prep Master Mix Set 1 Kit. Ligation of
adaptors was performed using 6 ml of the Illumina Multiplexing Sample Prepara-
tion Oliogonucleotide Kit. Libraries were size selected using 2% gel electrophoresis
and the distribution of fragments in the puriﬁed fraction was determined using the
Tapestation 1DK system (Agilent/Lab901). Each library was PCR enriched using
the following custom primers:
Multiplex PCR primer 1.0: 50-AATGATACGGCGACCACCGAGATCTACAC
TCTTTCCCTACACGACGCTCTTCCGATCT-30; index primer: 50-CAAGCAGA
AGACGGCATACGAGAT[INDEX]CAGTGACTGGAGTTCAGACGTGTGCTC
TTCCGATCT-30 .
Indexes were 8 bp long and part of an indexing system developed in-house.
Four independent PCR reactions per sample were prepared using 25% volume of
the pre-PCR library each. After eight cycles of PCR (cycling conditions as per
Illumina recommendations), the four reactions were pooled and puriﬁed with
AmpureXp beads. The ﬁnal size distribution was determined using the Tapestation
1DK system (Agilent/Lab901). The concentration of each library was determined
by the Agilent qPCR Library Quantiﬁcation kit. Samples were sequenced using the
Illumina HiSeq2000 platform as paired 100 bp reads with Chemistry version 3.0,
with the aim of a target average coverage of 30 for the blood DNA and 60 for
the tumours.
After removal of PCR duplicates using Picard, reads were mapped with Stampy
version 1.0.12 (r975)18 onto the Human Reference Genome (GRCh37d5/hg19).
SNVs and small insertion–deletions (indels) were called with Platypus version 0.1.8
(ref. 19) using the tumour-normal pairs of bam ﬁles together to ensure comparable
calls at every locus. Variants were only called if they were assigned a sufﬁciently
high posterior probability (Phred score of 5). Additional ﬁlters were used to remove
variants in low-quality reads. Although we removed the allele bias to increase
sensitivity, we add ﬁlters on the number of high-quality reads at a location, carrying
the variants and overall. Similarly, we made use of the difference between log
likelihood ratios of each potential genotype to increase certainty. Finally, we made
sure that the automatic call matched the data by expert visual inspection of the
mapped reads onto the reference genome using read direction colouring on top of
the standard Integrative Genomics Viewer (IGV) scheme (http://
www.broadinstitute.org/igv/alignmentdata/). Variants were annotated with
ANNOVAR (RefSeq gene models) using: single nucleotide polymorphism database
(dbSNP) (132); 1,000 genomes project allele frequencies (November 2011);
University of California Santa Cruz (UCSC) segmental duplication scores; and
UCSC 46 species conservation scores. Candidate variants were annotated with
predictions of functional importance from SIFT and PolyPhen2.
Owing to the possibility of copy number changes and intra-tumour genetic
heterogeneity, we did not apply the default strand and allele bias ﬁlters to the data.
However, we selected only variants at sites with at least 10 reads. First calls were
compared between matched constitutional and tumour samples to identify somatic
mutations. Known variants present at frequency 40.05 in the 1,000 Genome
project, dbSNP or in the Exome Sequencing Project were also removed. Variants
identiﬁed in constitutional DNA from any of the other non-cancer sequencing
projects of the WGS500 consortium (29 million variants across 284 samples) were
discarded as being more likely due to systematic error in our pipeline than genuine
somatic mutation.
Ion Torrent sequencing. A custom 150 cancer-gene exome panel (details available
on request) was used for technical validation of the whole-genome sequencing in
the 15 bladder carcinomas. Approximately 100 ng DNA was used for sequencing.
Mean read depth was 1,380. Variants present in the genome and exome sequence
data were assessed alongside the equivalent Ion Torrent data, using both automatic
calls in the Torrent Server output and visual inspection using the IGV.
Targeted sequencing. Validation and replication were performed with bidirec-
tional Sanger sequencing of the coding regions of CDKN1A and of prioritized
regions (exons 8–11 and 17–25) of STAG2 (Supplementary Table 6). In addition,
well-established methods were used to screen for mutations in exons 5–8 of TP53.
Since neither CDKN1A nor STAG2 was present on the Ion Torrent cancer-gene
exome panel, we also sequenced these genes in the 15 cancers with genome or
exome sequence data. The somatic origin of any variation from the human
reference sequence was conﬁrmed by analysis of paired DNA from blood or
normal urothelium. All PCR reaction conditions are available on request. Muta-
tions were analysed with Mutation Surveyor V3.97 and conﬁrmed by inspection of
electropherograms.
Splice-site mutation analysis. To assess effects on mRNA splicing of the STAG2
mutation identiﬁed in the replication set of cancers, frozen bladder cancer was
homogenized using the gentleMACS homogenizer (Miltenyi Biotec) and RNA
isolated using TRIzol (Life Technologies). Bladder or pooled RNA from the First
Choice Human RNA panel (Ambion) was used as a negative control. The RNA was
treated with DNase I (Fermentas) to eliminate contaminating genomic DNA, and
cDNA synthesis was performed using the iScript cDNA synthesis kit (Bio-Rad).
Subsequently, PCR was performed on tumour or control cDNA using Phusion
High Fidelity PCR master-mix (Thermo Scientiﬁc) and the products examined by
minigel electrophoresis (Supplementary Table 6).
Structural variants. For analysis of copy number, LOH and ploidy, we used
the OncoSNP-Seq7 program, which identiﬁes variation based on read depth and
allelic fraction under various models of stromal contamination and ploidy. After
careful assessment of the data, we systematically chose the model with average
ploidy of the non-neoplastic part of the tumour closest to 2. Results were compiled
across the samples using the online version of GREVE to highlight recurrence of
changes20.
Breakdancer version 1.1.2 with default parameters was used to identify potential
rearrangements, focusing on inter-chromosomal translocations. Results were ﬁrst
ﬁltered for a score of 99, a minimum of 10 total supporting read pairs covering the
breakpoints. Looking for functional rearrangement, we then reduced the list to
breakpoints within genes and exons (Supplementary Data 2).
Single nucleotide polymorphism arrays. Ten tumour:normal pairs (451, 615,
635, 709, 745, 799, 2010, 3008, 3010 and 3034) were genotyped using the Illumina
Omni1 SNP array. The data were analysed using Genome Studio and OncoSNP21,
and used to test the validity of the next-generation sequencing calls as well as the
evaluation of copy number variation.
Prediction of effects of exonic mutations outside coding regions. MicroRNA
binding was assessed by the TargetScan 6.2 program for mammals (http://
www.targetscan.org/) across conserved and partly conserved miRNA families. In
addition, we examined the sno/miRNA track from the Human Genome Browser
(http://genome.ucsc.edu) based on miRBase Release 15.0 (April 2010) and snoR-
NABase Version 3. mRNA structure was assessed using RNAfold (http http://
rna.tbi.univie.ac.at/), using the default ‘minimum free energy and partition func-
tion option. In both cases, mutant and reference sequences were compared.
Clonal structure. Allelic heterogeneity, and thus clonal structure, was evaluated
using PyClone version 0.12.3.1 (ref. 22). Allelic frequencies of selected somatic
mutations were obtained using the number of reads and the number of reads
carrying a variant as the total copy number. The copy number value at each of
these loci and the tumour content were obtained from OncoSNP-Seq model
selection as described above. We performed the clonal structure assessment using
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the three most likely values of each cancer’s DNA index from OncoSNP-Seq—the
result from the estimate with the greatest likelihood is presented herein. Other
DNA index estimates produced modest quantitative differences in clonal structure
(data not shown), but these were insufﬁcient to alter qualitative conclusions
regarding clonality or to affect the analysis of clonal structure and
clinicopathological features of the cancers. For each sample, a speciﬁc set of
genome-wide somatic mutation was selected to characterize its heterogeneity: 50
randomly selected somatic mutations across the genome were added to the
candidate somatic mutations.
Pathway analysis. Pathway analysis was performed using the online version of
Intogen23 using the annotated, quality ﬁltered, somatic mutations from all 15
samples with genome-wide and exome-wide sequence data.
Immunohistochemistry. IHC analysis of p21 and p53 was carried out using a
standard avidin–biotin–peroxidase technique. Brieﬂy, TMA sections were dewaxed
and rehydrated through xylene, graded ethanol and water. Endogenous peroxidase
activity was blocked in 3% hydrogen peroxide for 20min before heat-induced
epitope retrieval at 110 C for 1min, in citrate buffer (10mM citric acid, 0.05%
Tween 20, pH 6.0) for p21 or Tris–EDTA buffer (10mM Tris base, 1mM EDTA
solution, 0.05% Tween 20, pH 9.0) for p53 sections, and samples allowed to cool at
room temperature to enhance antigen retrieval. After washing with running water
and TBS, endogenous protein-binding activity was quelled using avidin–biotin
blocking agent (Vector, Peterborough, UK) and 10% normal goat serum (Dako,
Cambridgeshire, UK). Sections were incubated with primary antibody diluted in
1% BSA (VWR International, Leicestershire, UK) at optimized dilutions: anti-p21
(1:20, 12D1, Cell Signalling), anti-p53 (1:50,000, DO-1, Santa-Cruz), at 4 C
overnight. The Dako REAL Detection System Peroxidase/DABþ Rabbit/Mouse kit
was then employed to determine immunoreactivity, as per manufacturer’s
instructions, with 1:50 (p21) and 1:200 (p53) dilutions of Dako REAL DABþ
Chromogen to Dako REAL HRP Substrate Buffer. Sections were washed, and then
counterstained for 15 s in ﬁltered Harris Haematoxylin (VWR, Leicestershire, UK),
before further washing, dehydration and mounting in dibutylphthalate xylene
(Leica, Peterborough, UK).
Slides were scanned using the Aperio ScanScope CS2 digital slide scanner at
 40 magniﬁcation and viewed using Aperio Image Scope viewing software.
Analysis of nuclear staining was made by two independent scorers by measuring
the percentage of positively stained tumour cells. A consensus was reached for
intensity by taking the mean if scores were within 20% of each other; otherwise,
images were reviewed and a consensus reached.
TCGA data. TCGA somatic exomic mutation data from 99 ‘bladder urothelial
carcinoma’ samples were obtained from the TCGA data portal (https://tcga-
data.nci.nih.gov/tcga/) on 31st October 2013.
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